Loading data for CAPR — first visit, this takes a few seconds.

Capricor Therapeutics, Inc. (CAPR)

NasdaqGS: CAPR · 실시간 가격 · USD

9.28

-0.61 (-6.17%)

종가 기준: Sep 04, 2026, 8:00 PM

9.37

-0.32%

애프터마켓: 7:51 PM

알림

Alert

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

데이터 없음

매수호가	9
시가총액	547M
매출 (ttm)	n/a
순이익 (ttm)	-129M
	0.72
	-2.48
	n/a
	-6.36
P/B (ttm)	2.22
P/S (ttm)	0.00
실적 발표일	Nov 10, 2026

매도호가	10.56
거래량	4,056,260
평균 거래량 (20일)	6,175,692
시가	9.83
전일 종가	9.89
일중 범위	9.14 - 9.93
52주 범위	2.96 - 40.37
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

CAPR 소개

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome prot...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Feb 13, 2007

직원 수 231

상장 거래소 NasdaqGS

티커 CAPR

웹사이트 https://www.capricor.com

전체 기업 정보

재무 실적

2025년 Capricor Therapeutics의 매출은 0로, 전년 22.27M 대비 -100% 감소했습니다. 순이익은 -105.04M로, 159.58% 증가했습니다.

재무제표

어닝 서프라이즈

Capricor Therapeutics가 Aug 13, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.
EPS -0.7 예상치 하회 -0.12, 및 -32.08% 전년 대비 감소.

다음 실적 발표

Capricor Therapeutics, Inc.의 실적 발표 예정일은 Nov 10, 2026, 정규장 중입니다.
애널리스트 예상 매출은 ... 업그레이드

주가가 움직인 이유

뉴스

3일 전 · MT Newswires

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index adding 0.6% and

3일 전 · InvestorsHub

Capricor Therapeutics shares rise 2.5% following August FDA update

Capricor Therapeutics (NASDAQ:CAPR) shares rose 2. 5% in pre-market trading to $10.

3일 전 · Stocktwits

Why Is CAPR Stock Rising Today? Piper Sandler Says Risk-Reward Favors Owning Stock Into FDA Decision

Piper Sandler upgraded Capricor to ‘Overweight’ from ‘Neutral’ and sharply raised the price target to $25, a roughly 150% upside potential from current levels.

1주 전 · Stocktwits

SRPT On Track For Best Week In 5 Months Ahead Of Late-2026 Clinical Data — Retail Eyes ‘Monumental Comeback’

Investors are now awaiting extra data from Sarepta’s mid-stage studies in two muscle diseases, facioscapulohumeral muscular dystrophy and myotonic dystrophy.

1주 전 · Insider Monkey

A Rejected Vote Pushes Capricor (CAPR) Toward A Narrower Path

On August 13, Capricor Therapeutics (NASDAQ:CAPR) held its second-quarter earnings call, just over two weeks after an FDA advisory committee voted 3 to 9 against the company’s bid to treat cardiomyopa...

2 페이지 중 1

Capricor Therapeutics, Inc. (CAPR)